HIV entry
Assets acting on this target.
- Class
- HIV entry inhibitor (monoclonal antibody)
Assets acting on this target.
1 of 1 assets (1 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| VH4527079 | ViiV Healthcare | HIV entry | HIV | Ph 1 | An active ViiV Healthcare-sponsored Phase I trial (NCT06652958) is evaluating the safety and pharmacokinetics of VH4527079, a bispecific monoclonal antibody entry inhibitor, in healthy adults and persons with HIV, with expected completion in February 2027. | source ↗ |